title: Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome.
abstract: AIMS. Interleukin-37 (IL-37) is an anti-inflammatory cytokine. This study aims to investigate the concentrations of plasma and cerebrospinal fluid (CSF) IL-37 in patients with Guillain-Barré Syndrome (GBS).
  
  
  METHODS
  The levels of plasma and CSF IL-37, IL-17A, IFN- γ , and TNF- α in 25 GBS patients and 20 healthy controls (HC) were determined by enzyme-linked immunoabsorbent assay and flow cytometric bead array assay, respectively. The values of clinical parameters in the patients were also measured.
  
  
  RESULTS
  The concentrations of plasma IL-37, IL-17A, IFN- γ , and TNF- α and CSF IL-37 and IL-17A in patients at the acute phase of GBS were significantly higher than those in the HC. The levels of plasma IL-37, IL-17A, IFN- γ , and TNF- α were positively correlated in those patients, and the levels of CSF IL-37 and IL-17A as well as the levels of plasma TNF- α were correlated positively with the GBS disability scale scores (GDSs) in those patients. Treatment with intravenous immunoglobulin significantly reduced the levels of plasma IL-37, IL-17A, IFN- γ , and TNF- α in the drug-responding patients.
  
  
  CONCLUSIONS
  Our findings indicate higher levels of plasma and CSF IL-37 and IL-17A and other proinflammatory cytokines in patients with GBS.
authors.affiliation: Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, The Second Part of First Hospital, Jilin University, Changchun 130032, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Li
authors.forename: Pingwei
authors.initials: P
authors.lastname: Zhao
authors.forename: Xiguang
authors.initials: X
authors.lastname: Sun
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Che
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005786:Gene Expression Regulation; D020275:Guillain-Barre Syndrome / Q000097:blood* / Q000134:cerebrospinal fluid*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007249:Inflammation / Q000378:metabolism; D007371:Interferon-gamma / Q000097:blood / Q000134:cerebrospinal fluid; D007375:Interleukin-1 / Q000097:blood* / Q000134:cerebrospinal fluid*; D020381:Interleukin-17 / Q000097:blood / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000134:cerebrospinal fluid; D055815:Young Adult
chemical_list: C508587:IL37 protein, human; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007375:Interleukin-1; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma